Page 84 - 《中国药房》2023年16期
P. 84

Angiotensin-neprilysin inhibition in heart failure with pre‐  a  real-world  12-week  study[J].  Eur  J  Pharmacol,2022,
               served ejection fraction[J]. N Engl J Med,2019,381(17):  928:175053.
               1609-1620.                                     [19]  秦少强,王亚玲,刘俊峰,等. 芪苈强心胶囊联合沙库巴
          [ 8 ]  周永越,徐兆龙. 沙库巴曲缬沙坦对射血分数中间值心                         曲缬沙坦钠片治疗慢性心功能不全临床效果[J]. 中华中
               力衰竭患者的预后影响[J]. 临床心血管病杂志,2021,37                     医药学刊,2020,38(4):201-203.
              (2):132-136.                                    [20]  MAGRI  G,BENTIVENGA C,COSENTINO  E R,et al.
          [ 9 ]  陈兆彦,孙强. 沙库巴曲缬沙坦对顽固性心力衰竭患者                         Management of a multicomorbid patient with heart failure
               康复治疗及左心室射血分数的影响[J]. 中华老年心脑血                         [J]. Cardiology,2017,138(Suppl 1):21-23.
               管病杂志,2021,23(4):379-382.                       [21]  RICCIO  G.  Pharmacological  management  of  a  heart  fai-
          [10]  李薇,高景芳,贾凡,等. 沙库巴曲缬沙坦对射血分数降                         lure patient with severe obesity[J]. Cardiology,2017,138
               低性心力衰竭患者心力衰竭易损期的疗效[J]. 中国临床                        (Suppl 1):11-12.
               药理学杂志,2021,37(14):1842-1845.                   [22]  CHENG  S,ZHANG  N,HUA  W.  Sacubitril/valsartan  in
          [11]  赖朝辉,刘迎午,王禹,等. 沙库巴曲缬沙坦钠对射血分                         the  management  of  heart  failure  patients  with  cardiac
               数减低的心力衰竭合并高血压患者血压及相关指标变                             implantable  electronic  devices[J].  Am  J  Cardiovasc
               化的研究[J]. 中华老年心脑血管病杂志,2022,24(1):                    Drugs,2021,21(4):383-393.
                                                              [23]  DE ANGELIS  G.  Management  of  patient  with  heart  fai-
               11-13.
                                                                   lure:Italian “field  practice”  experience  of  sacubitril/
          [12]  张跃,李宁,邱健,等. 血管紧张素受体脑啡肽酶抑制剂
                                                                   valsartan[J]. Curr Med Res Opin,2019,35(sup3):1-2.
               沙库巴曲缬沙坦治疗高血压的研究进展[J]. 中华高血压
                                                              [24]  GAZIANO T A,FONAROW G C,VELAZQUEZ E J,et
               杂志,2021,29(6):519-524.
                                                                   al.  Cost-effectiveness  of  sacubitril-valsartan  in  hospita-
          [13]  李锦爽,周浩,王万虹,等. 沙库巴曲缬沙坦对急性ST段
                                                                   lized patients who have heart failure with reduced ejection
               抬高型心肌梗死患者左室重构的影响[J]. 中国新药与临
                                                                   fraction[J]. JAMA Cardiol,2020,5(11):1236-1244.
               床杂志,2021,40(6):452-455.
                                                              [25]  张先林,路桥,李金龙,等. 沙库巴曲缬沙坦联合达格列
          [14]  李锦爽,戚冉冉,王万虹,等. 沙库巴曲缬沙坦钠对急性
                                                                   净与射血分数减低的心力衰竭临床疗效及预后的相关
               前壁心肌梗死合并急性心功能不全患者短期预后的影
                                                                   性[J]. 中华急诊医学杂志,2022,31(10):1396-1401.
               响[J]. 中国药房,2021,32(23):2890-2894.
                                                              [26]  秦园生,焦晓东,唐秀娥. 沙库巴曲缬沙坦联合达格列净
          [15]  陈莹恩,李建华,梁好,等 . 沙库巴曲缬沙坦在 5 例儿童
                                                                   治疗慢性心力衰竭合并 2 型糖尿病的临床疗效观察[J].
               扩张型心肌病中的应用并文献复习[J]. 中华实用儿科临
                                                                   临床和实验医学杂志,2022,21(10):1025-1030.
               床杂志,2021,36(24):1900-1902.
                                                              [27]  SPANNELLA F,GIULIETTI F,FILIPPONI A,et al. Ef‐
          [16]  王峥,韩淑芳,姚天明. 沙库巴曲缬沙坦治疗高龄慢性心
                                                                   fect of sacubitril/valsartan on renal function:a systematic
               力衰竭合并糖尿病患者临床疗效及安全性分析[J]. 临床
                                                                   review  and  meta-analysis  of  randomized  controlled  trials
               军医杂志,2021,49(5):539-542.
                                                                   [J]. ESC Heart Fail,2020,7(6):3487-3496.
          [17]  HSIAO  F  C,LIN  C  P,YU  C  C,et  al.  Angiotensin
                                                              [28]  SUEMATSU  Y,JING  W  H,NUNES  A,et  al.  LCZ696
               receptor-neprilysin inhibitors in patients with heart failure
                                                                  (sacubitril/valsartan),an  angiotensin-receptor  neprilysin
               with  reduced  ejection  fraction  and  advanced  chronic
                                                                   inhibitor,attenuates  cardiac  hypertrophy,fibrosis,and
               kidney disease:a retrospective multi-institutional study[J].
                                                                   vasculopathy in a rat model of chronic kidney disease[J]. J
               Front Cardiovasc Med,2022,9:794707.
                                                                   Card Fail,2018,24(4):266-275.
          [18]  JIA R Y,ZHANG X J,XU Y Z,et al. Effect of sacubitril/
                                                                            (收稿日期:2023-01-19  修回日期:2023-07-26)
               valsartan on renal function in patients with chronic kidney                        (编辑:陈    宏)
               disease and heart failure with preserved ejection fraction:
















          · 1994 ·    China Pharmacy  2023 Vol. 34  No. 16                            中国药房  2023年第34卷第16期
   79   80   81   82   83   84   85   86   87   88   89